(5Z)-3-(4-chlorophenyl)-5-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]imidazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (5Z)-3-(4-chlorophenyl)-5-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]imidazolidine-2,4-dione
• 化学式: C₂₁H₂₁ClN₄O₂
• 分子量: 396.9
• InChiKey: MNTCAKAVQXYCQK-JXAWBTAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] QUINOLINE DERIVATIVES<br/>[FR] DERIVES QUINOLINIQUES
  申请人：PFIZER PROD INC

  公开号：WO2004043929A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和n如定义所述，并且涉及所述化合物的药用可接受的盐。式I的化合物在激活5HT7受体方面具有活性，并且可用于治疗例如可以通过调节昼夜节律来治疗的疾病。
• 5HT7 Antagonists and inverse agonists
  申请人：Pfizer Inc.

  公开号：US20040229874A1

  公开（公告）日：2004-11-18

  The present invention relates to compounds of formula I, 1 and the pharmaceutically acceptable salts thereof. These compounds are useful as psychotherapeutic agents.

  本发明涉及公式I的化合物及其药用盐。这些化合物可用作心理治疗药物。
• Aralkyl and aralkylidene heterocyclic lactams and imides
  申请人：——

  公开号：US20020049214A1

  公开（公告）日：2002-04-25

  The present invention relates to compounds of the formula I 1 wherein R 1 , R 2 , R 3 , X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.

  本发明涉及公式I1中的化合物，其中R1、R2、R3、X、Y和虚线如规范中所定义，以及用于它们制备的中间体，含有它们的药物组合物以及它们作为精神治疗剂的药用。
• ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
  申请人：Pfizer Inc.

  公开号：US20020091117A1

  公开（公告）日：2002-07-11

  The present invention relates to compounds of the formula 1 wherein R 1 , R 2 , R 3 , X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.

  本发明涉及公式1的化合物，其中R1、R2、R3、X、Y和虚线在说明书中有定义，以及其制备的中间体，含有它们的制药组合物和它们的药用用途。这些化合物可用作心理治疗剂。
• Combination treatment for depression and anxiety
  申请人：——

  公开号：US20020049211A1

  公开（公告）日：2002-04-25

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT 1D receptor antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）的抑郁症或焦虑症的方法，通过给哺乳动物（例如人类）口服中枢神经系统穿透性NK-1受体拮抗剂（例如物质P受体拮抗剂）与5HT1D受体拮抗剂的组合。此外，本发明还涉及含有药学可接受载体、中枢神经系统穿透性NK-1受体拮抗剂和5HT1D受体拮抗剂的制药组合物。